Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 8Prostate Cancer Metastatic 2Neoplasms 2Recurrence 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-resistant Prostate Cancer 1Castrate-Resistant Prostate Cancer 1Adenocarcinoma 1

Interventions

enzalutamide 2cabazitaxel 2Prednisone 2Androgen Antagonists 2fludrocortisone acetate 1darolutamide 1XRP6258 1Radiosurgery 1Pluvicto 1Lutetium-177 1Lutetium 1Lenograstim 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Docetaxel 1Dexamethasone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Prostate Cancer Metastatic × cabazitaxel × Clear all
NCT02961257 2022-05-12

CABASTY

Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie

Phase 3 Completed
196 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT01254279 2015-01-21

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Sanofi

Phase 3 Completed
984 enrolled
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡